Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 6) Stocks In Focus Otonomy Reports Phase 1/2 Data For OTO-313 In Tinnitus, Revises Statistical Model For Late-Stage Otividex Program Following submission of a revised statistical analysis plan to the FDA with respect to its Phase 3 clinical trial of Otividex in Ménière's disease, Otonomy Inc (NASDAQ: OTIC) said the negative binomial model it has chosen to use — instead of the generalized Poisson model — allows it reduce the target patient enrollment in the ongoing trial from 160 to 142 patients while maintaining more than 90% power.Separately, the company said it intends to offer, subject to market and other conditions, a $300 million aggregate principal amount of convertible senior notes due 2025 in a private placement to qualified institutional buyers.